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Cell-selective knockout and 3D confocal image
analysis reveals separate roles for astrocyte-and
endothelial-derived CCL2 in neuroinflammation
Debayon Paul1†, Shujun Ge1*†, Yen Lemire1, Evan R Jellison2, David R Serwanski3, Nancy H Ruddle4
and Joel S Pachter1
Abstract
Background: Expression of chemokine CCL2 in the normal central nervous system (CNS) is nearly undetectable,
but is significantly upregulated and drives neuroinflammation during experimental autoimmune encephalomyelitis
(EAE), an animal model of multiple sclerosis which is considered a contributing factor in the human disease. As
astrocytes and brain microvascular endothelial cells (BMEC) forming the blood–brain barrier (BBB) are sources of
CCL2 in EAE and other neuroinflammatory conditions, it is unclear if one or both CCL2 pools are critical to disease
and by what mechanism(s).
Methods: Mice with selective CCL2 gene knockout (KO) in astrocytes (Astro KO) or endothelial cells (Endo KO) were used
to evaluate the respective contributions of these sources to neuroinflammation, i.e., clinical disease progression, BBB
damage, and parenchymal leukocyte invasion in a myelin oligodendrocyte glycoprotein peptide (MOG35-55)-induced
EAE model. High-resolution 3-dimensional (3D) immunofluorescence confocal microscopy and colloidal gold
immuno-electron microscopy were employed to confirm sites of CCL2 expression, and 3D immunofluorescence
confocal microscopy utilized to assess inflammatory responses along the CNS microvasculature.
Results: Cell-selective loss of CCL2 immunoreactivity was demonstrated in the respective KO mice. Compared to
wild-type (WT) mice, Astro KO mice showed reduced EAE severity but similar onset, while Endo KO mice displayed
near normal severity but significantly delayed onset. Neither of the KO mice showed deficits in T cell proliferation, or
IL-17 and IFN-γ production, following MOG35-55 exposure in vitro, or altered MOG-major histocompatibility complex
class II tetramer binding. 3D confocal imaging further revealed distinct actions of the two CCL2 pools in the CNS. Astro
KOs lacked the CNS leukocyte penetration and disrupted immunostaining of CLN-5 at the BBB seen during early EAE in
WT mice, while Endo KOs uniquely displayed leukocytes stalled in the microvascular lumen.
Conclusions: These results point to astrocyte and endothelial pools of CCL2 each regulating different stages of
neuroinflammation in EAE, and carry implications for drug delivery in neuroinflammatory disease.
Keywords: Astrocytes, Blood–brain barrier, Brain microvascular endothelial cells, CCL2, Claudin-5, Central nervous system,
Experimental autoimmune encephalomyelitis, Neuroinflammation, 3D confocal imaging
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Background
The chemokine CCL2 (formerly called Monocyte Chemo-
attractant Protein-1, MCP-1) has long been established as
a critical mediator of inflammation within and outside the
central nervous system (CNS), and stimulates extravasa-
tion of mononuclear leukocytes into CNS and peripheral
tissue beds [1-5]. Elevated CNS expression of CCL2 has
been a consistent observation among the different para-
digms of experimental autoimmune encephalomyelitis
(EAE) [6-8], a CNS demyelinating inflammatory disease
that serves as a model for multiple sclerosis. This chemo-
kine’s singular importance in driving EAE was demon-
strated by global CCL2 knockout (KO) mice (CCL2−/−),
which showed diminished severity and delay in onset of
disease in C57BL/6 mice actively immunized with myelin
oligodendrocyte glycoprotein35-55 (MOG35-55) [9]. Adop-
tive transfer EAE experiments also revealed effector T cells
from MOG-immunized CCL2−/− mice could transfer EAE
to naïve wild-type (WT) recipients, while encephalitogenic
T cells from WT donors were unable to induce EAE in
CCL2−/− mice [9]. Bone marrow chimera studies further
showed active immunization EAE was markedly reduced
when bone marrow from WT mice was engrafted into
lethally irradiated CCL2−/− mice, but not when bone
marrow from CCL2−/− mice was transferred into WT
recipients [10]. Collectively, these findings of induced
CNS expression of CCL2 during EAE, together with
the adoptive transfer and bone marrow chimera stud-
ies, are consistent with a prominent role for CNS
CCL2 in mediating EAE and diminish or negate the
pathogenic impact of CCL2 from the peripheral leukocyte
compartment.
What remains unclear, however, is which specific sources
of CCL2 significantly contribute to disease, whether any
reside locally in the CNS, their pathogenic mechanisms,
and how they might be targeted therapeutically. Astrocytes
are a major CNS source of CCL2 in both EAE and multiple
sclerosis (MS) [7,8,11]. By projecting their endfeet toward
the abluminal surface of brain microvascular endothelial
cells (BMEC) that form the blood–brain barrier (BBB), as-
trocytes are ideally situated to intimately modulate BBB
function and CNS leukocyte extravasation [12]. Our la-
boratory [13] and others [14,15] have demonstrated that
CCL2 can disrupt integrity of cultured BMEC along with
causing redistribution and reduction in expression of tight
junction (TJ) proteins. A priori, CCL2 released from astro-
cyte endfeet may be partly responsible for the loss of BBB
properties that accompanies both EAE [16] and MS [17],
assisting development of a chemotactic gradient across the
microvascular wall to drive the migration of adhered
leukocytes past the endothelium, and/or further guid-
ing extravasated leukocytes into the CNS parenchyma
[18]. In addition to astrocytes, BMECs have also been
shown to express CCL2 during EAE [19] and MS [20].
The observations that anti-CCL2 antibody prohibits
firm attachment of leukocytes in vivo to CNS pial ve-
nules of mice immunized for EAE [21], and inhibits
monocyte transendothelial migration across cultured
BMEC [22], support the concept that CCL2 presented
on the luminal endothelial surface aids in arresting
leukocytes prior to their extravasation. The recent de-
scription that transendothelial migration of lympho-
cytes is mediated, in part, by intraendothelial vesicle
stores of CCL2 [23], further accents a novel role for
the endothelium as a critical source of this chemokine.
To resolve the respective contributions of astrocyte
and endothelial cell CCL2 to neuroinflammation, we de-
veloped cell-conditional chemokine KO mice, in which
the CCL2 gene was selectively eliminated in each of
these cell types [24]. Here we report for the first time
that targeted CCL2 gene deletion from either astrocytes
or endothelial cells abates EAE pathogenesis, while dif-
ferentially affecting separate aspects of CNS leukocyte
extravasation and clinical disease course.
Materials and methods
Animals
Astrocyte and endothelial cell-specific CCL2 knockout
(KO) mice were generated by intercrossing mice containing
a floxed CCL2 allele with transgenic mice of glial fibrillary
acid protein (GFAP)-Cre or Tie2-background, respectively,
and have been previously characterized in detail [24].
Astrocyte-specific KO mice are referred to as Astro KO,
and endothelial specific KO mice as Endo KO mice
throughout this study. KO mice and their wild-type
(WT) littermate controls were housed in specific pathogen-
free conditions. All procedures involving animals were
performed in accordance with the Animal Care and
Use Guidelines of the University of Connecticut Health
Center(Animal Welfare Assurance #A3471-01).
EAE induction
EAE was induced by active immunization with MOG35-55
peptide (MEVGWYRSPFSRVVHLYRNGK; W. M. Keck
Biotechnology Resource Center, Yale University), as previ-
ously described [25]. Briefly, on day 0 (d0), female mice 8
to 10 weeks of age were injected subcutaneously into the
right and left flanks with a total of 300 μg of MOG peptide
in complete Freund’s adjuvant containing 300 μg Myco-
bacterium tuberculosis (DIFCO). Mice were also injected
intraperitoneally with 500 ng pertussis toxin (List Labora-
tories) in phosphate buffered saline (PBS, Gibco/BRL) on
d0 and d2 post-immunization (p.i.) to heighten the auto-
immune reaction to MOG35-55 peptide [26,27].
Clinical assessment of EAE
Mice were scored daily for clinical disease severity accord-
ing to the following scale: 0 = normal; 1 = tail limpness;
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2 = limp tail and weakness of hind legs; 3 = limp tail
and complete paralysis of hind legs; 4 = limp tail, complete
hind leg and partial front leg paralysis; and 5 = death. Sev-
eral disease parameters were calculated as described [28].
The Mean Day of Onset was calculated by averaging the
time when clinical symptoms; i.e., a clinical score of ≥1,
were first observed for two consecutive days in each
mouse. The Mean Maximum Clinical Score was calcu-
lated by averaging the highest score for each mouse. The
Disease Index was calculated by adding the daily average
clinical scores in each group, dividing by the mean day of
onset, and multiplying by 100. If an animal showed no dis-
ease, the day of onset was arbitrarily counted as one day
after the last day of the experiment. Disease Incidence was
the fraction of mice experiencing EAE.
Cell culture and cytokine assay
MOG35-55-immunized mice were sacrificed and draining
lymph nodes were dissected on d12. Mashed lymph
nodes were pressed through a 70 μm mesh into cold
RPMI. Cells were pelleted at 450 g at 4°C for 5 min and
resuspended in red blood cell lysis buffer (Sigma) on ice
for 5 min. After three washes with cold PBS, cells were
stained with 0.4% Trypan blue (Sigma Aldrich) and
counted with the Countess® Automated Cell Counter
(Invitrogen) to permit discrimination of dead cells.
Single cell suspensions of lymph node cells (LNCs)
were prepared and cultured in 24-well plates (Corning)
at 1 × 106 viable cells/mL in RPMI 1640 supplemented with
10% fetal bovine serum, 1.25% HEPES buffer, 1% sodium
pyruvate, 1% penicillin-streptomycin, 1% glutamine, 1%
non-essential amino acids, 0.01% 0.05M 2-mercaptoethanol
(Sigma Aldrich). LNCs were restimulated with a combin-
ation of 10 μg/mL MOG35-55 and 0.5 ng/mL interleukin-12
(IL-12) (R&D Systems). Cytokines present in the cell culture
supernatants of LNC were quantified using the multiplex
enzyme-linked immunosorbent assay (ELISA) kit (R&D
Systems).
Proliferation assay
LNCs were prepared as for the cytokine assay. Cells
were pulse-labeled with 2 μΜ carboxyfluoresceinsuccini-
midyl ester (CFSE, Molecular Probes) in RPMI for 5 min
at room temperature. After extensive washing with PBS,
the CFSE-labeled cells were suspended and cultured in
complete medium, as above, in 24-well plates (2 × 106/
well) for 72 h. Cell viability was assessed by Trypan blue
exclusion. The LNC samples were washed in fluorescence-
activated cell sorting (FACS) buffer (1% FCS and 0.1%
sodium azide in PBS). After blocking with Fc Block
(BD Biosciences) at 4°C for 20 min in the dark, the
cells were washed and stained with fluorochrome-
labeled antibodies against murine CD3, CD4, and CD11a
(BD Biosciences) at 4°C for 30 min. After the cells were
washed, the fluorescence intensities were measured by a
FACS LSRII flow cytometer (BD Biosciences) and the fol-
lowing parameters were determined using FlowJo software
(Treestar): % divided (percentage of cells in original popu-
lation that has divided); Division Index (average number
of cell divisions that a cell in the original population has
undergone); Proliferation Index (total number of divi-
sions/number of cells that went into division); Expansion
Index (fold-expansion of overall culture); and Replication
Index (fold-expansion of only responding cells).
MOG38-49 MHC class II tetramer binding assay
The MOG38-49 MHC class II tetramer binding assay was
based on that of Cravens et al. [29]. LNCs from MOG35-55-
immunized mice were prepared and cultured as for cyto-
kine and proliferation assays for 72 h. Thereafter, LNCs
were washed with FACS buffer, and blocked with Fc Block
in FACS buffer at 4°C for 20 min in the dark. LNCs were
washed again, and MOG38-49 major histocompatibility
complex (MHC) class II tetramer-PE or MHC class II con-
trol tetramer-PE hCLIP103-117-PE (obtained from the NIH
Tetramer Core Facility) were added and incubated at 37°C
for 1 hour in the dark. After incubation, the cells were dir-
ectly stained with fluorochrome-labeled antibodies against
murine CD4, CD11a, and CD44 at 4°C for 30 min. LNCs
were washed and resuspended in FACS buffer. Samples
were acquired on a FACS LSRII flow cytometer (BD
Biosciences) and the data analyzed using FlowJo soft-
ware (Treestar). Cells were gated as single live CD4+ T
lymphocytes and examined for CD11a, CD44, and
tetramer reactivity. Cells that were MOG tetramer-
positive and CD11a+ were considered MOG-specific
and previously activated.
Immunofluorescence and 3D analysis of confocal z-stack
images
Tissue was prepared as described by Paul et al. [30]. In
brief, following transcardiac perfusion/fixation of mice,
spinal cords were removed by laminectomy and freeze-
embedded in cryomatrix. Subsequently, 12 × 60 μm cryo-
sections from the thoraco-lumbar region, approximately
between the T10 and L3 vertebrae were adhered to poly-
L-lysine coated slides. Following staining, sections were
mounted in Mowiol® prior to microscopic analysis.
For immunodetection of CCL2, affinity-purified rabbit
anti-mouse CCL2 (Peprotech) was utilized with a corre-
sponding anti-rabbit Alexa® 555-conjugated antibody
(Life Technologies). Sections were subsequently double-
immunostained with either rat anti-mouse CD31 (BD
Pharmingen) followed by secondary incubation with
anti-rat Alexa® 488 (Life Technologies) to highlight the
endothelium, or Alexa® 488-conjugated anti-mouse GFAP
(Life Technologies) to identify astrocytes. To specifically
enhance detection of CCL2, which shows dispersed
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punctate immunoreactivity, confocal z-stacks were first
deconvolved using AutoQuant ×3 (Media Cybernetics)
software to correct for z-axis distortion. This significantly
improved z-resolution and the resulting high-resolution
images were exported into Imaris® (Bitplane Inc.). Repre-
sentative z-slices, showing the co-localization of CCL2
with endothelial CD31 or astrocyte marker GFAP were
then obtained.
For 3D quantification of microvascular tight-junction
protein claudin-5 (CLN-5) density, the protocol recently
detailed by Paul et al. [30] was used. The microvascular
basement membrane (BM), a fusion of the respective
endothelial and parenchymal BMs [31], was labeled with
rabbit anti-mouse Laminin 1 (Lam 1) (Cedarlane) and
anti-rabbit Alexa® 555 (Life Technologies). Anti-mouse
Claudin-5-Alexa® 488 (Life Technologies) was employed
to highlight TJs. Additionally, nuclear stain DRAQ5
(Biostatus Ltd.) was utilized to reveal the perivascular
cellularity surrounding inflamed CNS microvessels, iden-
tified as venules [30], due to leukocyte extravasation.
Spinal cord venules from comparable regions of the
dorsolateral white matter were imaged. Confocal z-stacks
were acquired at 1-μm increments between z-slices, fol-
lowing a multitrack scan, using a Zeiss LSM 510 Meta
confocal microscope equipped with a 40× Fluar (NA 1.3)
and a 63× Plan-neofluar (NA 1.25) oil immersion lens.
Confocal z-stacks were imported into Imaris® (version 7.6)
software (Bitplane Inc.) and the venule of interest was seg-
mented out from rest of the 3D dataset by manually tra-
cing the vessel contour in each confocal z-slice, followed
by merging the z-slice contours into a 3D contour surface.
Surface area of the generated 3D contour was used as an
estimate of the microvascular “surface area” defined by
the endothelial layer. The CLN-5 channel was isosurface
rendered (within the 3D contour surface) and the density
of CLN-5 staining calculated as Total CLN-5 intensity/
Microvascular surface area. CLN-5 density values were
expressed as mean ± standard error of the mean (SEM).
To optically isolate (3D segmentation) and resolve the
DRAQ5+ cellularity associated with leukocyte accumula-
tion in the luminal or perivascular compartments of an
inflamed venule [30], confocal z-stacks of venules reveal-
ing a cross-sectional view were acquired and imported
into Imaris®. The venule of interest was then isolated
from rest of the 3D dataset by creating a 3D contour
surface, defining the parenchymal BM. This effectively
eliminated the parenchymal cellularity (i.e., extravascular
infiltrates). Additionally, the lumen was segmented out
in a similar manner, by creating another 3D surface, ap-
proximating the contour of the endothelial BM (Endo
BM). Spatial location of the observed cellularity between
the BMs was considered perivascular (Additional file 1).
To graphically resolve the distribution of DRAQ5+ lu-
minal and perivascular cells along microvascular x, y,
and z axes with respect to the endothelial and parenchy-
mal BMs, a 3D volume was first constructed from the
acquired confocal z-stack, followed by 3D segmentation
of the luminal and perivascular compartments as de-
scribed above. Imaris® spot creation wizard was then
employed to represent each of the DRAQ+ nuclei as a
“spot object” in 3D space. Only DRAQ5+ nuclei >3 μm
in diameter were considered. The 3D profiles of the cre-
ated spot objects, representing the position of luminal
and perivascular leukocytes, were then plotted on a 3D
Imaris® Vantage plot to reveal its spatial location.
Immuno-electron microscopy (Immuno-EM)
Colloidal gold detection of CNS microvascular CCL2
immunoreactivity by immuno-EM was performed as de-
scribed previously [32]. WT mice at d16 EAE were anes-
thetized as described above, and subjected to transcardiac
perfusion/fixation with Ringer’s solution, pH 6.9, followed
by 4% paraformaldehyde, 0.1% glutaraldehyde in 0.1M
phosphate buffer (PB), pH 7.4. Vibratome sections of
spinal cord (300–500 μm thick) were cryoprotected with
2M sucrose in PB and plunge-frozen in liquid propane
cooled by liquid nitrogen (−186°C). Sections were stained
en bloc with 1.5% uranyl acetate in anhydrous methanol
at −90°C for 30 hours and infiltrated with Lowicryl
HM20 resin (Polysciences), followed by polymerization
with UV light for 72 hours in a freeze-substitution in-
strument (Leica AFS) in a temperature gradient (−45°C
to 0°C). Sections (70–80 nm thick) were cut and col-
lected onto 400-mesh gold-gilded nickel grids coated
with a Coat-Quick “G” pen (Daido). Tissue sections
were incubated with anti-mouse CCL2 antibody (Pepro-
tech), followed by incubation with goat anti-mouse IgG
labeled with colloidal gold particles of 12 nm diameter
(Jackson ImmunoResearch). After immunoreaction, tis-
sue sections were counterstained with 2% uranyl acetate
and then with 2% lead citrate. Primary antibody was omit-
ted in immunoreaction as a control, and yielded no de-
tectable gold labeling.
Statistical analysis
For analysis of cell-specific KO on clinical EAE parame-
ters, a χ2 test was used for comparisons of disease inci-
dence; a Mann–Whitney U-test was used for comparisons
of disease severity; and ANOVA, followed by Bonferroni’s
multiple comparison post-hoc analysis, were used for
comparison of disease onset [33]. ANOVA/Bonferroni
post-hoc tests were also employed to assess differences in
CLN-5 density values [30]. To contrast the rate of rise of
clinical EAE progression among the different mouse
groups, linear regression was performed on data points
beginning at the onset of disease through attainment of
the plateau or highest score. Statistical analyses were
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performed employing Prism 5 software (GraphPad), and
results were considered significant at P ≤0.05.
Results
Astro KO and Endo KO mice show cell-selective loss of
CCL2
Immunofluorescent staining of CCL2 in spinal cord dur-
ing EAE in Astro KO, Endo KO, and WT mice is shown
in high-resolution z-stack confocal images in Figure 1.
Using identical image acquisition parameters, no CCL2
staining was detected either in naïve mice, or EAE mice
in the absence of primary antibody (Additional file 2:
Figure S1), thus highlighting specific immunoreactivity
to inflamed CNS tissue. In WT mice at d16 post-EAE in-
duction, CCL2 staining was vessel-associated as well as
within the perivascular space (Figure 1a). Notably, CCL2
staining appeared aligned with inter-endothelial junc-
tions (CD31), and showed a punctate distribution rather
than a diffuse appearance throughout the cytoplasm.
This could reflect containment of CCL2 within vesicles,
as recently described by Shulman et al. [23] for cultured
human umbilical vein endothelial cells (HUVECs). A
representative z-slice further revealed intense double
staining (CCL2 and CD31) of the endothelial layer. Par-
enchymal CCL2 staining (Figure 1b) was largely observed
in association with GFAP+ astrocytes. Localization within
astrocytes was confirmed in a representative z-slice. Some
large deposits of CCL2 could also be seen just outside the
astrocytes, which may indicate secreted chemokine. Both
endothelial and astrocyte immunoreactivity in WT mice
with EAE were confirmed by immuno-electron micros-
copy (Figure 1c–f ). Notably, CCL2 immunoreactivity was
detected within the inter-endothelial junctions (Figure 1c),
and could also be seen in association with endothelial
vesicular-like structures (Figure 1d). There was also abun-
dant immunoreactivity within cellular processes at the
abluminal side of the endothelium, possibly representing
CCL2 destined for or contained within astrocyte endfeet
(Figure 1e–f ).
The CCL2 staining patterns with both KO mice were
markedly different (Figure 2). Astro KO mice at d16
(Figure 2a) showed vessel-associated CCL2 staining
but greatly diminished staining in the perivascular space.
Conversely, Endo KO mice (Figure 2b) exhibited a near
absence of vessel-associated CCL2 staining, while robust
CCL2+ astrocytes were still clearly evident. These staining
patterns are consistent with previous results from this la-
boratory showing CCL2 RNA expression by both micro-
vessel and parenchymal fractions of brain and spinal cord
from WT mice with EAE [33], and argue that CCL2 pro-
tein is produced by astrocytes and BMECs, and not merely
taken up at these sites.
That some vessels in Astro KO mice and some astro-
cytes in Endo KO mice appeared devoid of CCL2
staining possibly reflects that not all of the respective
endothelial cell and astrocyte populations became similarly
inflamed, a prospect supported by only a subset of vessels/
vessel segments being associated with leukocyte infiltrates
(data not shown). It may further be that CCL2 from endo-
thelial cells or astrocytes exerts some positive control over
CCL2 expression by the other cell type [24,34].
Astro KO and Endo KO mice are both resistant to EAE, but
show different clinical phenotypes
Figure 3a,b shows that targeted CCL2 gene eliminations
in astrocytes and endothelial cells, respectively, promin-
ently affected development of EAE, consistent with earl-
ier reports of the effects of global CCL2 knockout [9,10].
While the incidence of disease was largely unaffected in
both KO mice compared to WT, there was clear evi-
dence of altered disease progression in the two cell-
selective CCL2 KO groups. Astro KO mice exhibited
significantly reduced disease severity (clinical score)
compared with WT littermates throughout the time
frame observed, along with just a slight, insignificant
delay in disease onset. In sharp contrast and nearly
mirror image effect, Endo KO mice showed only mild
reduction in disease severity, but a significantly pro-
tracted delay in the onset of disease. It was further ob-
served that the rate of rise of clinical disease, as
reflected by the slope of the linear, ascending region of
the disease score graphs, was different between Astro
KO and Endo KO mice. Astro KO mice showed a lesser
rate of rise of clinical disease than both WT and Endo
KO mice, while the latter two mouse groups showed
similar rates of disease rise. Thus, it appears that while
disease was significantly delayed in Endo KO mice,
once disease commenced it proceeded on a normal
time course (for the period evaluated). Comparisons of
Disease Incidence, Mean Day of Onset, Mean Max-
imum Clinical Score, and Disease Index in Astro KO,
Endo KO, and WT mice are tabulated in Figure 3c.
Astro KO and Endo KO mice do not show different
MOG-specific T cell responses
Endo KO mice have the CCL2 gene eliminated from all
endothelial cells, central and peripheral. This could
mean that observed alterations in EAE disease progres-
sion in Endo KO mice might stem from a defect in the
afferent immune arm, such as attenuated T cell priming.
Indeed, this possibility is prompted by findings that
CCL2 is expressed and presented by high endothelial ve-
nules in lymph nodes [35], instrumental in dendritic cell
maturation [36], and released by dendritic cells to attract
antigen-specific T cells [37]. Hence, several T cell prolifera-
tion parameters – % Divided, Division Index, Proliferation
Index, Expansion Index, and Replication Index – were
assayed in CSFE pulse-labeled LNC cultures from
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MOG-immunized Astro KO, Endo KO, and WT mice
(Figure 4a). Following restimulation with MOG, no
significant differences were detected among cells from
the three types of mice for any of these parameters. This
is in agreement with previous findings that indicated no
difference in T cell proliferation between LNC cultures
fromWT and global CCL2−/− mice [9].
We also assayed the ability of cultured LNCs from
each of these mice to produce IFN-γ or IL-17, which are
cytokines considered instrumental in autoimmunity and
Figure 1 CCL2 expression in spinal cord of WT mice during EAE. (a–b) z-stack confocal images from spinal cord cryosections of WT mice at
d16 EAE are shown, revealing staining of CCL2 (red), and CD31 or GFAP (green) to delineate the endothelial cells and astrocytes, respectively.
CCL2 staining was isosurface rendered for enhanced spatial perspective. (a) WT mice express CCL2 both along the CD31+ microvascular endothelium,
where staining appears aligned along the endothelial junctions, and within the perivascular space (left). (b) CCL2 staining is also associated with GFAP+
astrocytes (right). Insets show co-localization of CCL2 with CD31 or GFAP (yellow) in a single z-slice from the respective regions marked by the hatched
white boxes, or CCL2 (red) channel alone. (c–f) Colloidal gold immuno-EM localization of CCL2 localization along microvessels in sections of spinal cord
from mice at d16 EAE. (c) CCL2 immunoreactivity is localized within the inter-endothelial junction (arrow) and scattered throughout the endothelial
cytoplasm. (d) A cluster of CCL2 immunoreactivity (arrow) is shown in close apposition to an endothelial vesicular structure that is near the
plasma membrane. (e) Low magnification showing cross-section of a microvessel (possibly a postcapillary venule or small venule) and punctate
distribution of CCL2 immunoreactivity in the perivascular space (arrows). (f) Higher magnification, revealing a high density of CCL2 immunoreactivity in
and around what may represent astrocyte endfeet (arrows). Results are representative of 5–7 sections sampled from three mice in each group and
two independent experiments. Scale bars are noted on the respective images.
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EAE [38], in response to restimulation with MOG.
Figure 4b shows that MOG-stimulated expression of
neither cytokine was significantly altered in Astro KO
or Endo KO mice compared to their WT cohorts. Earlier,
Huang et al. [9] had described diminished production of
IFN-γ in LNCs from CCL2−/− mice, which might reflect
the effects of having depleted a peripheral CCL2 pool dis-
tinct from that of endothelial cells. Figure 4c further re-
veals that, following MOG immunization, the percentage
of MOG38-49 MHC class II tetramer positive CD4 T cells
Figure 2 CCL2 expression in spinal cord of Astro KO and Endo KO during EAE. Representative z-stack confocal images from spinal cord cryosections
of KO mice at d16 EAE are depicted. Cell-specific CCL2-KO mice display loss of CCL2 staining in respective targeted cell types. (a) Astro KO mice show
venule-associated CCL2 staining, but lack staining in the parenchymal astrocytes (left). (b) In contrast, Endo KO mice are deficient in vessel-associated
CCL2 staining, but maintain astrocyte staining (right). The endothelial boundary is marked with yellow lines. Insets show co-localization of CCL2 with
CD31 or GFAP (yellow) in a single z-slice from the respective regions marked by the hatched white boxes, or CCL2 (red) channel alone. Results are
representative of 5–7 sections sampled from three mice in each group and two independent experiments.
Figure 3 Astro KO and Endo KO mice show different patterns of clinical EAE. EAE was induced in WT, Astro KO, and Endo KO mice by
MOG35-55 immunization; all mice were observed daily and scored for clinical disease for 30 days. Each group consisted of 5–6 mice, and analysis
was performed in triplicate. Graphs represent mean data points from all three analyses ± standard error. (a) Mean clinical EAE scores. Astro KO
mice do not attain as severe disease as WT during the evaluation period, while Endo KO mice approach WT disease severity but do so only after
significantly delayed onset. The rate of rise of clinical disease, as reflected by the slope of each regression line (hatched lines) through the
respective ascending disease scores for the different mice, is similar in both WT and Endo KO mice, but notably less in Astro KO mice. (b) Disease
incidence. All mice show a similar incidence of disease but, compared to WT mice, Astro KO mice show only a mild delay while Endo KO mice
show a prolonged delay in disease onset. (c) Summary of various clinical disease parameters among the three mouse groups.
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was in line with another report [29] and similar in LNCs
from Astro KO, Endo KO, or WT mice, indicating that the
frequency of MOG-specific T cells was comparable among
these groups. Hence, our results argue against either
astrocyte- or endothelial cell-targeted CCL2 gene deletion
having significantly impaired peripheral T cell behavior
and immune responsiveness to MOG peptide. These find-
ings are further in accord with reports that MOG-specific,
encephalitogenic T cells can be generated in mice with
global knockout of CCL2 [9].
Astro KO and Endo KO mice display altered inflammatory
responses along the CNS microvasculature during EAE
Given the different clinical EAE phenotypes of Astro KO
and Endo KO mice with apparent absence of overt im-
pact on T cell priming, we next sought to determine ef-
fects of cell selective CCL2 loss on inflammatory events
along the CNS microvasculature. 3D perspective projection
views of confocal reconstructions were generated using
Imaris® to provide a more realistic 3D representation of the
z-stack dataset. Notable differences in staining of CLN-5, a
prominent TJ protein in CNS microvessels and BBB deter-
minant [39], were found among WT, Astro KO, and Endo
KO mice during EAE (Figure 5), while naïve mice of all
groups showed no evidence of disparities (data not shown).
At d9, prior to evidence of clinical disease, WT mice
showed focal fragmentation of the CLN-5 staining pattern.
This discontinuous appearance of CLN-5 staining in re-
gions of increased perivascular cellularity was not a result
of CLN-5 staining being distributed in z-planes not cap-
tured during acquisition, as the confocal reconstructions
shown represent 3D images generated from 60 × 1-μm
thick z-slices. Rather, the areas lacking immunostaining
reflected actual sites of CLN-5 disruption associated with ex-
travasating leukocytes. This picture differed significantly from
that seen with naïve mice, where CLN-5 immunostaining
Figure 4 LNCs from MOG35-55-immunized WT, Astro KO, and Endo KO mice show similar responses to MOG35-55restimulation in vitro.
LNCs were prepared from MOG35-55-immunized mice on d12, and restimulated with MOG35-55 for 72 h in culture, after which time different
responses were measured. (a) T cell proliferation. LNC were pulse-labeled with 2 μΜ CFSE for 5 min at the beginning of culture and analyzed after
72 h by FACS, gating on CD3, CD4, CD11a. (b) Cytokine production. The concentrations of IL-17 and IFN-γ were determined in supernatants of
LNC after 72 h in culture. (c) Binding of MOG38-49 MHC class II tetramer-PE. Binding was determined after 72 h in culture, and hCLIP103-117
tetramer-PE served as a control for non-specific binding. Plots were gated on CD4+ T lymphocytes. The frequency of MOG38-49 I-A
b tetramer+
CD4+ T cells is similar among WT, Astro KO, and Endo KO groups, while hCLIP103-117 I-A
b tetramer does not bind cultured T cells. The data shown
are representative of at least two independent experiments; data in (a) and (b) reflect mean value ± standard error.
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appeared continuous, without obvious interruptions, and
perivascular cellularity was absent (Additional file 3:
Figure S2). Hence, for the purpose of highlighting the
pathologic role(s) of CCL2 released from astrocyte and
endothelial sources in neuroinflammation, statistical
comparisons for CLN-5 density were only made be-
tween WT, Astro KO, and Endo KO mice during evolv-
ing EAE. The significantly altered CLN-5 pattern
observed in WT mice during EAE corresponded with a
sharp decrease of approximately 60% in the density of
CLN-5 staining. In stark comparison, Astro KO mice
demonstrated little if any change in CLN-5 staining,
while Endo KO mice displayed a somewhat intermedi-
ate response at this time-point. By d16- following dis-
ease onset- WT mice showed further disruption and
loss of CLN-5 staining, down approximately 80% from
that demonstrated by naïve mice. Astro KO mice at
this later time showed a precipitous loss of CLN-5
staining, declining by approximately 60% (compared to
naïve and d9 mice), while Endo KO mice at d16
showed only a moderate, non-significant CLN-5 de-
crease of approximately 19% (compared to d9).
Differences in leukocyte infiltration patterns were also
obvious among the various strains of mice when vessels
were viewed in longitudinal- and cross-section (Figure 6).
During neuroinflammation, the BM splits into its re-
spective endothelial and parenchymal components [31],
highlighting two spaces: the subendothelial space (be-
tween the endothelium and endothelial BM) and the
perivascular space (between the endothelial BM and the
parenchymal BM). Both these spaces swell with leuko-
cytes that have recently extravasated across the BMECs,
Figure 5 Astro KO and Endo KO mice show differential loss of CLN-5 staining in spinal venules during EAE. (a) Isosurface-rendered images
were generated from confocal z-stacks of 60 μm thick thoraco-lumbar spinal cord cryosections at d9 and d16 EAE, as described in Materials and
Methods. Staining of CLN-5 (green isosurface) and nuclei/DRAQ5 (blue) is shown. Larger images displaying 3D perspective projection views of
confocal reconstructions show CLN-5 channel only, to emphasize the fragmented pattern of TJ protein staining. Inserts depict both CLN-5 and
nuclei, highlighting the close association of altered CLN-5 staining with dense perivascular cellularity representing infiltrating leukocytes. Arrows
demark overt gaps in CLN-5 staining, where the TJ pattern is clearly disrupted. Notably, CLN-5 staining pattern during EAE appears most intact in
Astro KO mice, least so in WT mice, and intermediate in Endo KO mice. (b) Quantification of CLN-5 staining as intensity per unit surface area of
the endothelium. CLN-5 density in naïve WT mice is included as a reference for the normal state, wherein the pattern of CLN-5 junctional staining
is continuous [30]. Statistical comparisons are between groups and within days. (c) Summary of CLN-5 changes. Statistical comparisons are within
groups and between days. A total of 12 venules were analyzed in each group sampled from three mice. Data reflect mean value ± standard
error. Scale = 20 μm.
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but as the BM becomes extensively fragmented during
this process, demarcation between the spaces is blurred
in longitudinal sections. Thus, in referring to leukocyte
distribution, the term “perivascular” is used herein to de-
scribe all extravasated leukocytes that are vessel-associated.
At d16, dense perivascular infiltrates were seen to be asso-
ciated with venules inWT mice, with cells apparently pene-
trating the parenchymal BM to enter the parenchyma
(Figure 6a,d). Astro KO mice showed similar type clusters
of perivascular cells, but no clear evidence of leukocytes in
the act of rupturing the parenchymal BM (Figure 6b,e). Ve-
nules of both WT (Figure 6d) and Astro KO (Figure 6e)
further exhibited lumens within which no cells were
detectable. By contrast, Endo KO mice alone displayed
aggregated cells apparently stalled in the lumen, as
well as a seemingly lesser extent of perivascular cells
(Figure 6c,f–h). To further resolve the aggregated cells
throughout the microvascular lumen of an entire 60
-μm section from Endo KO mice, and graphically dis-
tinguish this pattern from that in WT and Astro KO
mice, the distribution profiles of cells associated with
the lumen and perivascular space, respectively, were
mapped in 3D (Figure 7). Intra-luminal cells could
only be detected in Endo KO mice (Figure 7c). As the
actual number of spinal vessels showing any evidence
of inflammation was extremely low in Endo KO mice
at this time, the few examples detected showed this
common appearance of hindered leukocyte migration.
Moreover, since tissue was perfusion-fixed, these lu-
minal cells are not likely to have resulted from blood
stasis but, instead, suggest a possible deficit in extrava-
sation from CNS microvessels in Endo KO mice.
Discussion
While the critical role of CCL2 in EAE has been revealed
in global CCL2 knockout studies [9], and the chemokine
sources mediating this effect are suggested to reside in the
CNS [10], the identities of the sources responsible for spe-
cific neuroinflammatory events, e.g., effects at the BBB
and leukocyte penetration into the CNS, have not been re-
solved. In the present study, we used mice with targeted
CCL2 gene deletion in astrocytes or endothelial cells,
along with 3D confocal imaging, to establish - for the first
time – that CCL2 from each of these sources regulates dif-
ferent aspects of neuroinflammation and EAE course.
Astro KO mice exhibited a similar onset but reduced se-
verity of disease compared to WT, while Endo KO mice
displayed nearly the opposite clinical pattern. However,
neither of these KO mice showed any significant changes
in MOG-specific T cell responses in LNC cultures,
Figure 6 Astro KO and Endo KOmice display differences in perivascular cellularity associated with spinal venules during EAE. Isosurface-rendered
images were generated from confocal z-stacks of 60 μm cryosections at d16 EAE. Staining of BM Lam 1 (red), CLN-5 (green), and nuclei/DRAQ5 (blue) is
shown. (a, b, c) Longitudinal sections reveal the extent of vessel-associated leukocytes. CLN-5 staining is presented to highlight the endothelial boundary.
Insets represent enlarged view of areas highlighted in white hatched boxes, while double-headed arrows denote the space between the
endothelial and parenchymal BMs. All extravasated leukocytes within this space are considered “perivascular”. In WT mice, a dense accumulation
of DRAQ5+ perivascular cells (representing leukocytes) is seen, a few apparently penetrating the fragmented parenchymal BM (arrowhead). In Astro KO mice, a
similar dense perivascular cellularity is observed, with visibly intact parenchymal BM and lack of parenchymal leukocyte migration. In Endo KO mice, the BM is
also apparently intact, with minimal perivascular cellularity. Scale = 20 μm. (d, e, f) Cross-sections highlight the spatial distribution of vessel-associated
leukocytes. In WT mice, the vessel lumen (demarked by white dashes) appears empty and cells are seen in the perivascular space. A
few cells are visibly penetrating the parenchymal BM (arrowheads), alongwith dense parenchymal cellularity (brackets). In Astro KO mice,
the lumen again appears empty; congregated cells are evident in the perivascular space, with a few parenchymal clusters. In Endo KO
mice, cells are clearly present in the lumen, with apparently fewer cells in the perivascular space as compared to WT and Astro KO mice.
Parenchymal clustering is seemingly absent. The diffuse DRAQ5+ cells are likely parenchymal neural cells. (g-h) The red arrow designates the
same Endo KO image subject to contour-based 3D segmentation (see Materials and Methods) to further resolve luminal (blue) from perivascular (turquoise)
cells. Results are representative of 5–6 microvessels sampled from three mice in each group and two independent experiments. Scale = 10 μm.
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consistent with the observed effects of CCL2 gene de-
letion being limited to the CNS. Further reflecting
CNS action, Astro KO mice failed to show the paren-
chymal leukocyte infiltration and clear disruption of
CLN-5 that accompanied WT EAE, while Endo KO
mice revealed leukocytes apparently stalled in the lumen
of spinal cord microvessels. Significantly, the combined ef-
fect of separate astrocyte and endothelial CCL2 elimin-
ation on clinical disease closely mirrors the phenotype
reported when CCL2 gene ablation was confined to the
“central compartment” by adoptive transfer of WT T cells
[9] or transplantation ofWT bone marrow [10] into global
CCL2 KO mice; i.e., reduced disease severity along with
delayed disease onset. This reinforces the notion that
CCL2 from astrocytes and endothelial cells each contrib-
ute to EAE disease in a major, yet different way. The dif-
ferences in EAE noted between Astro KO and Endo KO
mice may reflect direct consequences of cell-specific
CCL2 release on the CNS microvascular endothelium,
leukocyte migration, or both. Possible actions of CCL2
released by CNS endothelial cells or astrocytes are sche-
matized in Figure 8.
Astrocyte-derived CCL2 regulates BBB integrity and
leukocyte penetration into the CNS parenchyma, while
endothelial-derived CCL2 impacts leukocyte transendothelial
migration
The failure of only Astro KO mice to show clear dis-
ruption of CLN-5 staining at d9 EAE supports the in-
terpretation that CCL2 released from astrocytes figures
prominently in destabilizing endothelial TJs at the
abluminal microvascular surface early during the neu-
roinflammatory process [13]. Later loss of CLN-5 in
these mice by d16 may, instead, reflect disruption of
TJs by extravasating leukocytes. Astrocyte-derived CCL2
may additionally serve to recruit extravasated leukocytes
into the parenchyma, as Astro KO mice revealed leuko-
cytes congregated in the perivascular space. This latter
role is supported by Carrillo-de Sauvage et al. [18], who
described contact of CNS infiltrating T cells with
Figure 7 Astro KO and Endo KO mice display differences in 3D distribution profiles of luminal and perivascular cells. Isosurface-rendered
images were generated from confocal z-stacks of 60-μm thick cryosections from WT, Astro KO, and Endo KO mice at d16 EAE. The BM is
highlighted by staining of Lam1 (red). (Top row) DRAQ5+ nuclei in luminal and perivascular compartments were optically isolated using 3D contour
based segmentation (as described in Materials and Methods), and pseudo-colored blue (luminal) and turquoise (perivascular), respectively. Using Imaris®
spot creation module, each of these nuclei is shown in the 3D dataset (volume) as a “spot object,” designating its luminal or perivascular location.
Scale = 10 μm. (Bottom row) Imaris® vantage plots showing the 3D distributions of luminal and perivascular cells along microvascular x, y, and z-axes
in the corresponding vessels from the top row. Scale = 20 μm. (a) Representative WT vessel showing an empty lumen (*). (b) The lumen in the Astro
KO vessel also appears empty (*) but partially collapsed, possibly owing to accumulation of perivascular cells that are missing guidance cues from
deleted astrocyte-derived CCL2. (c) In contrast, Endo KO vessel shows evidence of congregation of cells in the lumen (blue), possibly reflecting
stalled leukocyte transmigration in absence of endothelial-derived CCL2. Box-and-whisker plots are shown indicating the maximum and minimum
spread from the median, in μm, of luminal or perivascular nuclei along the x, y, and z-axes.
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CCL2-expressing perivascular astrocytes during neu-
roinflammatory disease.
The disruption of CLN-5-containing TJs during EAE
and its prominent control by astrocyte-derived CCL2, is
consistent with numerous reports on the action of CCL2
on TJs and BBB properties in cultured BMECs [13-15,40],
CNS microvessels in vitro [13], and CNS microvessels
in vivo in other neurological settings [41-43]. Notably,
however, a recent report describing the effect of pertussis
toxin injection in mice constitutively overexpressing
CCL2 selectively in oligodendrocytes under direction of
the myelin basic protein (MBP) promoter, found no evi-
dence of a disrupted CLN-5 pattern accompanying
leukocyte extravasation into brain [44]. This apparent
contradiction may be due, in part, to the high level of
chronic over-expression of CCL2 (<100,000 times nor-
mal values) having caused down-modulation of CCR2,
the cognate receptor for CCL2, on BMECs [45], as well
as inappropriate or inadequate access of oligodendrocyte-
derived CCL2 – normally not found in health or disease –
to the CNS microvasculature. The present study thus
underscores the unique relationship between endogen-
ous, astrocyte-derived CCL2, TJs, and BBB permeabil-
ity in neuroinflammatory disease [46].
Endothelial-derived CCL2, on the other hand, may fa-
cilitate a ‘post-adhesion’ stage of leukocyte extravasation,
as the absence of this chemokine pool was uniquely as-
sociated with the appearance of leukocytes stalled within
the microvascular lumen. In support of this hypothesis,
Shulman et al. [23] recently showed that an intraen-
dothelial vesicle pool of CCL2 within cultured HUVECs
is a critical regulator of transendothelial migration of ad-
herent effector T cells. Our data, showing both appar-
ently stalled leukocytes in the microvascular lumen of
Endo KO mice and punctate CCL2 immunostaining in
BMECs of WT mice, may thus represent an extension of
the results of Shulman et al. [23] to an in vivo scenario
and advance a critical role for a CNS endothelial pool of
CCL2, possibly vesicle bound, in mediating leukocyte
transendothelial migration during neuroinflammatory
disease. While this differs from the finding that CCL2
facilitates adhesion of leukocytes to pial microvessels
[21], this distinction may represent the considerable
endothelial heterogeneity that exists along the CNS
microvasculature [47].
The smaller but significant loss of CLN-5 staining
noted in Endo KO mice from d9 to d16 may chiefly rep-
resent the action of astrocyte-derived CCL2, as lesser
extravasation was observed in these mice during this
period. Conceivably, the astrocyte CCL2 pool could
also have guided the lesser amount of extravasated
cells into the parenchyma, resulting in the delayed dis-
ease noted.
Cell-selective CCL2 knockout highlights CNS actions of
CCL2 in neuroinflammatory disease
Our collective findings reinforce critical and non-redundant
roles of CNS CCL2 in mediating EAE, as previously impli-
cated in adoptive transfer and bone marrow chimera EAE
studies with global CCL2 knockout mice [9,10]. Of further
importance, the use of Astro KO and Endo KO mice to-
gether with high-resolution 3D confocal imaging in this
study was able to resolve apparently unique contributions of
astrocyte and endothelial CCL2 pools to EAE pathogenesis.
That both types of mice might share some effects of condi-
tional CCL2 deletion is in accord with reports that BMECs
can deposit CCL2 abluminally [48], and CCL2 can be trans-
cytosed from the abluminal to luminal BMEC surface [34].
Because all endothelial cells in the Endo KO mice are
deficient in CCL2 expression, at this time it cannot be
Figure 8 Differential actions of astrocyte-derived and endothelial cell-derived CCL2 at CNS venules. Based on observations with Astro KO and
Endo KO mice during EAE, the schematic depicts endothelial-derived CCL2 facilitating migration across the endothelium (1), a step post-adhesion.
Astrocyte-derived CCL2 is shown promoting both breakdown of endothelial tight junctions (2), and penetration of leukocytes across the parenchymal
BM into the CNS parenchyma (3).
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concluded that CCL2 from CNS endothelial cells, as
opposed to peripheral endothelial cells, affected the
disease process. However, given the failure of LNCs
from these mice to show any deficits in MOG-stimulated
proliferation, IFN-γ or IL-17 production, or MOG MHC
class II tetramer staining, it is doubtful that the absence of
CCL2 from peripheral endothelial cells was a major factor
in the aberrant EAE patterns noted. Diminished CLN-5
disruption and heightened presence of luminal leukocytes
in Endo KO mice further point to the CNS endothelial
pool of CCL2 as featuring critically in EAE.
Though only EAE was analyzed in this study, astro-
cytes and BMECs have been suspected as critical sources
of CCL2 during other neuroinflammatory conditions in-
vestigating three different CNS inflammatory scenarios
(human glioma, striatal injection of LPS in mice, and
adenovirally injected monkeys) reporting that extravasa-
tion of lymphocytes is mediated by CCL2-expressing as-
trocytes independent of the inflammatory situation and
species [18]. Further, Tei et al. [49] most recently argued
that CCL2 expression by both astrocytes and BMECs
may contribute to the invasion and parenchymal mi-
gration of brain Iba1+/NG2+ cells, descendants of sub-
populations of circulating monocytes, following cerebral
ischemia. Thus, expression of CCL2 by astrocytes and/or
BMECs may be considered a widespread phenomenon as-
sociated with neuroinflammation. The seminal import-
ance attributed to these particular sources of CCL2 does
not preclude contributions by other CCL2-expressing cell
types, e.g., microglia [10,50], which may further modulate
neuroinflammatory disease in their unique ways.
It has nevertheless been firmly established through ele-
gant adoptive T cell transfer [9] and bone marrow chimera
[10] studies, that CCL2 derived from the peripheral
leukocyte compartment is not critical to the development
of EAE. Hence, even though Tie-2-driven Cre expression
has been reported in cells of the hematopoietic lineage
[51], any potential loss of CCL2 from this population
would not detract from our interpretation that CCL2
elimination from BMEC, rather than leukocytes, predom-
inantly altered EAE disease. The delay of disease pheno-
type in Endo KO mice, in fact, is consistent with the lack
of CCL2 immunostaining in BMEC and apparent stalling
of adherent leukocytes observed in these animals.
Therapeutic targeting of CNS CCL2
Lastly, as the BBB has generally been recognized as the
major impediment to drug delivery to the CNS [52],
these results have significant implications for targeting
CCL2 in the treatment of neuroinflammatory disease. It
is thus notable to point out that injection of a CCL2-
neutralizing antibody directly into the brain was effective
at suppressing lymphocyte infiltration following striatal
lipopolysaccharide injection [18], a situation in which
astrocytes were observed to be the major CCL2-
expressing cell type. Arguably, therapeutic inhibition of
endothelial CCL2 would not require circumventing or
penetrating the BBB, in contrast to suppressing astrocyte
production of this chemokine. However, as our and the
recent results of Shulman et al. [23] point out, merely
targeting CCL2 with antibodies or receptor antagonists
may not be effective against vesicle-bound endothelial
CCL2 depots. The recent demonstration that the anti-
inflammatory compound bindarit, a synthetic indazolic
derivative (MWr 324 Daltons) that preferentially inhibits
transcription of the monocyte chemoattractant subfam-
ily of CC chemokines (MCP-1/CCL2, MCP-2/CCL8, and
MCP-3/CCL7), delayed and suppressed EAE in concert
with diminishing CNS microvascular CCL2 expression
[33], suggests that interfering with intra-endothelial
CCL2 might be of high therapeutic value. However, as
BBB disruption often accompanies neuroinflammatory
disease [30,47], drugs that inhibit CCL2 synthesis could
potentially have opportunity to strike at both endothelial
cells and astrocytes, even if only with limited efficiency
at the latter, and thus offer better therapeutic prospects
than antibodies or antagonists. Recent descriptions of
CCL2 involvement in post-ischemic disruption of the
BBB [43], beta-amyloid neurotoxicity [53], and traumatic
brain injury [54], further underscore that modulating
CNS CCL2 synthesis at the vascular and/or parenchymal
level may offer a novel therapeutic option for a wide
range of neuropathologies.
Conclusions
In light of our results, it is determined that CCL2 from
either astrocytes or BMECs separately impacts clinical
EAE and associated neuroinflammatory processes in dis-
tinct ways and through different mechanisms depending
on the source cell type. CCL2 from astrocytes regulates
severity of clinical EAE disease, while controlling pene-
tration of leukocytes into the CNS parenchyma and
disrupting CLN-5 staining pattern along the CNS mi-
crovasculature. In contrast, CCL2 from BMECs ap-
pears to more so determine disease onset, and effect
post-adhesion leukocyte transendothelial migration.
Therapeutic targeting of CCL2 expression or action at
the parenchymal and/or vascular levels may thus offer
promise in treating neuroinflammatory disease.
Additional files
Additional file 1: Contour-based 3D segmentation of luminal- and
perivascular-associated cells in Endo KO mice during EAE. The video
shows 3D reconstruction of the representative Endo KO venule from
Figure 7, allowing for enhanced visualization of the perivascular and
luminal cellularity associated with the microvessel along x, y, and z axes.
It further demonstrates the sequential steps employed for the
contour-based 3D segmentation of DRAQ5+ cells into separate luminal
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and perivascular compartments, using 3D contour surfaces, as described in
Materials and Methods. The nuclei were pseudo-colored in blue (luminal)
and turquoise (perivascular). Each 180°-turn in the video indicates the
following steps in sequence - 3D reconstruction→ Lam1 (Red) isosurface→
parenchymal BM contour→ endothelial BM contour→ segmented nuclei.
Additional file 2: Figure S1. Specificity of CCL2 immunostaining.
Volume rendered images of z-stacks obtained from serialsections of d9
EAE spinal cords used in Figure 6 (left) and naïve (right) mice demonstrating
specific immunoreactivity of the CCL2 antibody. No detectable CCL2 staining
(green) was observed in naïve mice upon incubation with CCL2 antibody or
in EAE mice in the absence of primary antibody. The endothelium is
highlighted with CD31 (red), while DRAQ5 staining reveals the nuclei (blue).
Scale = 20 μm.
Additional file 3: Figure S2. Lack of focal CLN-5 immunostaining loss
and perivascular cellularity in naïve spinal microvessels. Isosurface-rendered
images generated from confocal z-stacks of 60 -μm thick cryosections from
naïve mice showing continuity of CLN-5 staining (green) in naïve spinal
microvessels. The lack of perivascular cellularity associated with typical
inflamed microvessels is further highlighted with DRAQ5 staining for
nuclei (blue). Scale = 20 μm.
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